Interview with Jane Provis Evans, Head cGMP services at Nanopharm
In the ever-evolving world of pharmaceuticals, the importance of stringent quality control cannot be overstated. This interview with Jane Provis-Evans, Head of cGMP Analysis at Nanopharm, sheds light on the critical role of cGMP testing in the development and optimization of drug-device combinations, particularly for orally inhaled and nasal drug products (OINDPs). With the launch of Nanopharm’s new GMP services, the company is well-positioned to help clients bring innovative treatments to patients.
Dry Powder Inhaler Formulations: Microstructural Analysis Techniques
The paper titled “Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques” explores the use of advanced analytical methods to improve our understanding of the performance of dry powder inhalers (DPIs).
Exploring PBPK Modeling in Nasal Drug Delivery: Expert Insights from Will Ganley
Explore PBPK modeling for OINDP and nasal drug delivery, optimizing drug development and reducing clinical trial needs
Nanopharm & Fluidda Discuss FDA’s New Inhaled Product Guidelines
Explore how alternative bioequivalence methods, including computational fluid dynamics and in silico modeling, are shaping the future of generic drug approval.
Interview with Rob Bootle: Advancements in Nanopharm’s OINDPs
Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs).
Nanopharm Newsletter May 2023
Explore Nanopharm’s SmartTrack™ for OINDPs and uncover the role of PBPK in nasal drug delivery.
Alternative regulatory path for generic Respiratory Products
Explore Nanopharm’s SmartTrack, an alternative solution for FDA approval of generic inhalation drug delivery products.
Trade Marks Registration Certificate for Nanopharm Ltd
Discover Nanopharm’s leading role in pharmaceutical research, specializing in OINDP, nasal, and inhaled pharmaceutical solutions.
